Literature DB >> 19339719

HPV screening for cervical cancer in rural India.

Rengaswamy Sankaranarayanan1, Bhagwan M Nene, Surendra S Shastri, Kasturi Jayant, Richard Muwonge, Atul M Budukh, Sanjay Hingmire, Sylla G Malvi, Ranjit Thorat, Ashok Kothari, Roshan Chinoy, Rohini Kelkar, Shubhada Kane, Sangeetha Desai, Vijay R Keskar, Raghevendra Rajeshwarkar, Nandkumar Panse, Ketayun A Dinshaw.   

Abstract

BACKGROUND: In October 1999, we began to measure the effect of a single round of screening by testing for human papillomavirus (HPV), cytologic testing, or visual inspection of the cervix with acetic acid (VIA) on the incidence of cervical cancer and the associated rates of death in the Osmanabad district in India.
METHODS: In this cluster-randomized trial, 52 clusters of villages, with a total of 131,746 healthy women between the ages of 30 and 59 years, were randomly assigned to four groups of 13 clusters each. The groups were randomly assigned to undergo screening by HPV testing (34,126 women), cytologic testing (32,058), or VIA (34,074) or to receive standard care (31,488, control group). Women who had positive results on screening underwent colposcopy and directed biopsies, and those with cervical precancerous lesions or cancer received appropriate treatment.
RESULTS: In the HPV-testing group, cervical cancer was diagnosed in 127 subjects (of whom 39 had stage II or higher), as compared with 118 subjects (of whom 82 had advanced disease) in the control group (hazard ratio for the detection of advanced cancer in the HPV-testing group, 0.47; 95% confidence interval [CI], 0.32 to 0.69). There were 34 deaths from cancer in the HPV-testing group, as compared with 64 in the control group (hazard ratio, 0.52; 95% CI, 0.33 to 0.83). No significant reductions in the numbers of advanced cancers or deaths were observed in the cytologic-testing group or in the VIA group, as compared with the control group. Mild adverse events were reported in 0.1% of screened women.
CONCLUSIONS: In a low-resource setting, a single round of HPV testing was associated with a significant reduction in the numbers of advanced cervical cancers and deaths from cervical cancer. 2009 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339719     DOI: 10.1056/NEJMoa0808516

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  370 in total

1.  Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer.

Authors:  Johannes Schweizer; Peter S Lu; Charles W Mahoney; Marthe Berard-Bergery; Minh Ho; Valli Ramasamy; Jon E Silver; Arnima Bisht; Yassine Labiad; Roger B Peck; Jeanette Lim; Jose Jeronimo; Roslyn Howard; Patti E Gravitt; Philip E Castle
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies.

Authors:  Julia C Gage; Kayode O Ajenifuja; Nicolas A Wentzensen; Akinfolarin C Adepiti; Claire Eklund; Mary Reilly; Martha Hutchinson; Sholom Wacholder; Joe Harford; Amr S Soliman; Robert D Burk; Mark Schiffman
Journal:  Int J Cancer       Date:  2011-08-05       Impact factor: 7.396

3.  Gynecological cancer: More evidence supporting human papillomavirus testing.

Authors:  Philip E Castle
Journal:  Nat Rev Clin Oncol       Date:  2012-02-14       Impact factor: 66.675

4.  HPV genotype detection using hybrid capture sample preparation combined with whole genome amplification and multiplex detection with Luminex XMAP.

Authors:  Brian Lowe; Lori Kobayashi; Attila Lorincz; Rick Mallonee; Dominic O'Neil; Ha Thai; Irina Nazarenko
Journal:  J Mol Diagn       Date:  2010-09-16       Impact factor: 5.568

5.  Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India.

Authors:  Haripriya Vedantham; Michelle I Silver; B Kalpana; C Rekha; B P Karuna; K Vidyadhari; S Mrudula; Brigitte M Ronnett; K Vijayaraghavan; Gayatri Ramakrishna; Pavani Sowjanya; Shantha Laxmi; Keerti V Shah; Patti E Gravitt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

6.  Screening: HPV testing for cervical cancer: the good, the bad, and the ugly.

Authors:  Philip E Castle
Journal:  Nat Rev Clin Oncol       Date:  2010-07       Impact factor: 66.675

7.  Preventing cervical cancer globally by acting locally: if not now, when?

Authors:  Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2010-09-30       Impact factor: 13.506

8.  Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?

Authors:  Joel Fokom Domgue; Mark Schiffman; Nicolas H Wentzensen; Julia C Gage; Philip E Castle; Tina R Raine-Bennett; Barbara Fetterman; Thomas Lorey; Nancy E Poitras; Brian Befano; Yi Xie; Lais S Miachon; Michael Dean
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

9.  The Peru Cervical Cancer Prevention Study (PERCAPS): the technology to make screening accessible.

Authors:  Kimberly L Levinson; Carolina Abuelo; Jorge Salmeron; Eunice Chyung; Jing Zou; Suzanne E Belinson; Guixiang Wang; Carlos Santos Ortiz; Carlos Santiago Vallejos; Jerome L Belinson
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

Review 10.  Advancing cervical cancer prevention in India: implementation science priorities.

Authors:  Suneeta Krishnan; Emily Madsen; Deborah Porterfield; Beena Varghese
Journal:  Oncologist       Date:  2013-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.